Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker SGP
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Feb 17, 2026 | SCHEDULE 13G | SGP SpyGlass Pharma, Inc. | Srinivas Akkaraju | 2.11M | 6.3% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G | SGP SpyGlass Pharma, Inc. | Samsara Opportunity Fund GP, LLC | 625,000 | 1.9% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G | SGP SpyGlass Pharma, Inc. | Samsara Opportunity Fund, L.P. | 625,000 | 1.9% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G | SGP SpyGlass Pharma, Inc. | Samsara BioCapital GP, LLC | 1.48M | 4.5% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G | SGP SpyGlass Pharma, Inc. | Samsara BioCapital, L.P. | 1.48M | 4.5% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | RA Capital Nexus Fund III, L.P. | 2.05M | 6.2% | SCHEDULE 13D ↗ |
| Feb 17, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | RA Capital Healthcare Fund, L.P. | 5.97M | 17.9% | SCHEDULE 13D ↗ |
| Feb 17, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | Rajeev Shah | 8.02M | 24.1% | SCHEDULE 13D ↗ |
| Feb 17, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | Peter Kolchinsky | 8.02M | 24.1% | SCHEDULE 13D ↗ |
| Feb 17, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | RA Capital Management, L.P. | 8.02M | 24.1% | SCHEDULE 13D ↗ |
| Feb 13, 2026 | SCHEDULE 13G | SGP SpyGlass Pharma, Inc. | Frank M. Sands | 2.50M | 7.8% | SCHEDULE 13G ↗ |
| Feb 13, 2026 | SCHEDULE 13G | SGP SpyGlass Pharma, Inc. | Sands Capital Alternatives, LLC | 420,797 | 1.3% | SCHEDULE 13G ↗ |
| Feb 13, 2026 | SCHEDULE 13G | SGP SpyGlass Pharma, Inc. | Sands Capital Life Sciences Pulse Fund III-Holdings, L.P. | 2.08M | 6.5% | SCHEDULE 13G ↗ |
| Feb 13, 2026 | SCHEDULE 13G | SGP SpyGlass Pharma, Inc. | Sands Capital Life Sciences Pulse Fund III (DE), L.P. | 420,797 | 1.3% | SCHEDULE 13G ↗ |
| Feb 13, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | Martemanshurk B.V. | 2.19M | 6.6% | SCHEDULE 13D ↗ |
| Feb 13, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | Manapouri B.V. | 2.19M | 6.6% | SCHEDULE 13D ↗ |
| Feb 13, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | Cooperatieve Gilde Healthcare VG VI U.A. | 2.19M | 6.6% | SCHEDULE 13D ↗ |
| Feb 13, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | Gilde Healthcare VG VI Management B.V. | 2.19M | 6.6% | SCHEDULE 13D ↗ |
| Feb 13, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | Gilde Healthcare Holding B.V. | 2.19M | 6.6% | SCHEDULE 13D ↗ |
| Feb 13, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | Rick Yang | 6.04M | 18.1% | SCHEDULE 13D ↗ |
| Feb 13, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | Paul Walker | 7.39M | 22.2% | SCHEDULE 13D ↗ |
| Feb 13, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | Scott D. Sandell | 7.39M | 22.2% | SCHEDULE 13D ↗ |
| Feb 13, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | Edward T. Mathers | 6.04M | 18.1% | SCHEDULE 13D ↗ |
| Feb 13, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | Mohamad H. Makhzoumi | 7.39M | 22.2% | SCHEDULE 13D ↗ |
| Feb 13, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | Anthony A. Florence, Jr. | 7.39M | 22.2% | SCHEDULE 13D ↗ |
| Feb 13, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | Carmen Chang | 7.39M | 22.2% | SCHEDULE 13D ↗ |
| Feb 13, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | Ali Behbahani | 7.39M | 22.2% | SCHEDULE 13D ↗ |
| Feb 13, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | Forest Baskett | 7.39M | 22.2% | SCHEDULE 13D ↗ |
| Feb 13, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | Nea 16 GP, LLC | 7.39M | 22.2% | SCHEDULE 13D ↗ |
| Feb 13, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | NEA Partners 16, L.P. | 7.39M | 22.2% | SCHEDULE 13D ↗ |
| Feb 13, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | New Enterprise Associates 16, L.P. | 7.39M | 22.2% | SCHEDULE 13D ↗ |
| Feb 13, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | Nea 17 GP, LLC | 7.39M | 22.2% | SCHEDULE 13D ↗ |
| Feb 13, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | NEA Partners 17, L.P. | 7.39M | 22.2% | SCHEDULE 13D ↗ |
| Feb 13, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | New Enterprise Associates 17, L.P. | 7.39M | 22.2% | SCHEDULE 13D ↗ |
| Feb 10, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | Peter Justin Klein | 3.31M | 9.9% | SCHEDULE 13D ↗ |
| Feb 10, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | Kirk Nielsen | 3.31M | 9.9% | SCHEDULE 13D ↗ |
| Feb 10, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | Vensana Capital I, L.P. | 3.31M | 9.9% | SCHEDULE 13D ↗ |
| Feb 10, 2026 | SCHEDULE 13D | SGP SpyGlass Pharma, Inc. | Vensana Capital I GP, LLC | 3.31M | 9.9% | SCHEDULE 13D ↗ |
38 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:31 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances